Disease · MONDO_0021640
Comparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 16 of 16
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Bevacizumab Resistant Patients vs Bevacizumab Naive Patients: Number of Participants With Adverse Events | 44 of 44 | 43 of 43 | 87 | NCT00923117 | Trial comparisons |
| Bevacizumab Resistant Patients vs Bevacizumab Naive Patients: serious adverse events | 16 of 44 | 13 of 43 | 87 | NCT00923117 | Trial comparisons |
| Phase I (Erlotinib & Temsirolimus) vs Phase II (Erlotinib & Erlotinib): serious adverse events | 3 of 21 | 2 of 59 | 80 | NCT00112736 | Trial comparisons |
| Anaplastic Tumors vs Glioblastoma Multiforme: serious adverse events | 8 of 31 | 16 of 43 | 74 | NCT00504660 | Trial comparisons |
| Arm I - Anaplastic Glioma vs Arm 2 - Glioblastoma: Safety Profile - Events That Discontinued Treatment | 8 of 16 | 6 of 42 | 58 | NCT00369590 | Trial comparisons |
| Phase 1 Dose Escalation - Romidepsin vs Phase 2 Dose From Phase 1 - Romidepsin: serious adverse events | 0 of 8 | 0 of 40 | 48 | NCT00085540 | Trial comparisons |
| Treatment (Bendamustine Hydrochloride) for Glioblastoma vs Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma: Toxic Death | 0 of 16 | 0 of 29 | 45 | NCT00823797 | Trial comparisons |
| Treatment (Bendamustine Hydrochloride) for Glioblastoma vs Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma: PFS-6 | 1 of 16 | 8 of 29 | 45 | NCT00823797 | Trial comparisons |
| Tandutinib & Bevacizumab in GBM Patients vs Tandutinib & Bevacizumab in AG Patients: Number of Participants With Adverse Events | 40 of 41 | 1 of 1 | 42 | NCT00667394 | Trial comparisons |
| Tandutinib & Bevacizumab in GBM Patients vs Tandutinib & Bevacizumab in AG Patients: serious adverse events | 15 of 41 | 0 of 1 | 42 | NCT00667394 | Trial comparisons |
| Positive Expression vs Negative Expression: Association of Biomarkers and One-year Survival - EGFR vIII | 1 of 5 | 7 of 17 | 22 | NCT00671970 | Trial comparisons |
| Positive Expression vs Negative Expression: Association of Biomarkers and One-year Survival - Epidermal Growth Factor (EGFR) | 7 of 20 | 0 of 1 | 21 | NCT00671970 | Trial comparisons |
| Intact vs Loss: Association of Biomarkers and One-year Survival - Phosphatase and Tensin Homologue (PTEN) | 1 of 2 | 7 of 19 | 21 | NCT00671970 | Trial comparisons |
| Positive Expression vs Negative Expression: Association of Biomarkers and One-year Survival - Phosphorylated Protein Kinase B (pAKT) | 6 of 16 | 1 of 2 | 18 | NCT00671970 | Trial comparisons |
| Positive Expression vs Negative Expression: Association of Biomarkers and One-year Survival - Phosphorylated Mitogen-activated Protein Kinase (pMAPK) | 5 of 12 | 1 of 4 | 16 | NCT00671970 | Trial comparisons |
Phase I Dose Level I Sorafenib 400mg Twice Daily + Everolimus 5mg Daily vs Phase I Dose Level -1 Sorafenib 400mg Twice Daily, 7 Days on, 7 Off + Everolimus 5mg Daily: Number of Participants With a Dose-limiting Toxicity (DLT) | 3 of 6 | 1 of 6 | 12 | NCT01434602 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021640/comparisons